Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Citigroup's Rating of Ascendis Pharma A/S on 5/18/2026

On May 18, 2026, Citigroup updated its outlook on Ascendis Pharma A/S (NASDAQ:ASND) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.